Expression of Mucin Family Proteins in Non-Small-Cell Lung Cancer and its Role in Evaluation of Prognosis

Tu, Jing; Tang, Min; Li, Guoqing; Chen, Liang; Wang, Yübo; Huang, Yong

doi:10.1155/2022/4181658

Cited by 5 publications

(3 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MUC1 is a transmembrane glycoprotein that is aberrantly glycosylated and overexpressed in a variety of epithelial cancers. Previous studies have confirmed that MUC1 is overexpressed in NSCLC tissues [ 75 , 76 ], and in about 70% of ovarian cancer [ 77 ]. Tumor-associated MUC1 (tMUC1) is different from the MUC1 expressed in normal cells and can be used as a biomarker and therapeutic target of cancer [ 78 ].…”

Section: Car T-cell Therapy In Solid Tumorsmentioning

confidence: 87%

Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors

Chen

Lü

2022

Cancers

View full text Add to dashboard Cite

Immunotherapy has been the fifth pillar of cancer treatment in the past decade. Chimeric antigen receptor (CAR) T-cell therapy is a newly designed adoptive immunotherapy that is able to target and further eliminate cancer cells by engaging with MHC-independent tumor-antigens. CAR T-cell therapy has exhibited conspicuous clinical efficacy in hematological malignancies, but more than half of patients will relapse. Of note, the efficacy of CAR T-cell therapy has been even more disappointing in solid tumors. These challenges mainly include (1) the failures of CAR T-cells to treat highly heterogeneous solid tumors due to the difficulty in identifying unique tumor antigen targets, (2) the expression of target antigens in non-cancer cells, (3) the inability of CAR T-cells to effectively infiltrate solid tumors, (4) the short lifespan and lack of persistence of CAR T-cells, and (5) cytokine release syndrome and neurotoxicity. In combination with these characteristics, the ideal CAR T-cell therapy for solid tumors should maintain adequate T-cell response over a long term while sparing healthy tissues. This article reviewed the status, clinical application, efficacy, safety, and challenges of CAR T-cell therapies, as well as the latest progress of CAR T-cell therapies for solid tumors. In addition, the potential strategies to improve the efficacy of CAR T-cells and prevent side effects in solid tumors were also explored.

show abstract

Section: Car T-cell Therapy In Solid Tumorsmentioning

confidence: 87%

Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors

Chen

Lü

2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Mucins have recently received significant attention as potential biomarkers. Primarily, mucins have become increasingly recognized as valuable biomarkers in a wide spectrum of cancers, including lung cancer [42][43][44][45][46][47][48][49][50][51][52]. Therefore, mucins present potential molecular targets for cancer therapy [53][54][55][56].…”

Section: Discussionmentioning

confidence: 99%

Mucins 3A and 3B Are Expressed in the Epithelium of Human Large Airway

Merikallio,

Pincikova,

Kotortsi

et al. 2023

IJMS

View full text Add to dashboard Cite

Aberrant mucus secretion is a hallmark of chronic obstructive pulmonary disease (COPD). Expression of the membrane-tethered mucins 3A and 3B (MUC3A, MUC3B) in human lung is largely unknown. In this observational cross-sectional study, we recruited subjects 45–65 years old from the general population of Stockholm, Sweden, during the years 2007–2011. Bronchial mucosal biopsies, bronchial brushings, and bronchoalveolar lavage fluid (BALF) were retrieved from COPD patients (n = 38), healthy never-smokers (n = 40), and smokers with normal lung function (n = 40). Protein expression of MUC3A and MUC3B in bronchial mucosal biopsies was assessed by immunohistochemical staining. In a subgroup of subjects (n = 28), MUC3A and MUC3B mRNAs were quantified in bronchial brushings using microarray. Non-parametric tests were used to perform correlation and group comparison analyses. A value of p < 0.05 was considered statistically significant. MUC3A and MUC3B immunohistochemical expression was localized to ciliated cells. MUC3B was also expressed in basal cells. MUC3A and MUC3B immunohistochemical expression was equal in all study groups but subjects with emphysema had higher MUC3A expression, compared to those without emphysema. Smokers had higher mRNA levels of MUC3A and MUC3B than non-smokers. MUC3A and MUC3B mRNA were higher in male subjects and correlated negatively with expiratory air flows. MUC3B mRNA correlated positively with total cell concentration and macrophage percentage, and negatively with CD4/CD8 T cell ratio in BALF. We concluded that MUC3A and MUC3B in large airways may be a marker of disease or may play a role in the pathophysiology of airway obstruction.

show abstract

“…The MUC gene family, CLDN gene family, and ZNF gene family were among the regulated genes selected for univariate COX analysis, based on previous reports [ [19] , [20] , [21] ]. Following this, the R package “ConsensusClusterPlus” [ 22 ] was used to perform consensus clustering of the subtypes within the cohort.…”

Section: Methodsmentioning

confidence: 99%

Prognostic role of MUCIN family and its relationship with immune characteristics and tumor biology in diffuse-type gastric cancer

Luo,

Li,

Wang

et al. 2024

Heliyon

View full text Add to dashboard Cite

Expression of Mucin Family Proteins in Non-Small-Cell Lung Cancer and its Role in Evaluation of Prognosis

Cited by 5 publications

References 51 publications

Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors

Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors

Mucins 3A and 3B Are Expressed in the Epithelium of Human Large Airway

Prognostic role of MUCIN family and its relationship with immune characteristics and tumor biology in diffuse-type gastric cancer

Contact Info

Product

Resources

About